vs
Side-by-side financial comparison of ClearPoint Neuro, Inc. (CLPT) and SHOULDER INNOVATIONS, INC. (SI). Click either name above to swap in a different company.
SHOULDER INNOVATIONS, INC. is the larger business by last-quarter revenue ($11.8M vs $10.4M, roughly 1.1× ClearPoint Neuro, Inc.). SHOULDER INNOVATIONS, INC. produced more free cash flow last quarter ($-11.4M vs $-12.1M).
ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.
Shoulder Innovations, Inc. is a medical technology firm specializing in design, development, and commercialization of innovative orthopedic devices for shoulder replacement surgery. Its products reduce surgical complications, improve patient outcomes, and are sold to orthopedic surgeons and healthcare providers across North America and Western Europe.
CLPT vs SI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.4M | $11.8M |
| Net Profit | — | $-8.7M |
| Gross Margin | 61.5% | 76.2% |
| Operating Margin | -67.7% | -65.0% |
| Net Margin | — | -74.3% |
| Revenue YoY | 34.0% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.26 | $-0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.4M | — | ||
| Q3 25 | $8.9M | $11.8M | ||
| Q2 25 | $9.2M | $11.0M | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $7.8M | — | ||
| Q3 24 | $8.1M | — | ||
| Q2 24 | $7.9M | — | ||
| Q1 24 | $7.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-5.9M | $-8.7M | ||
| Q2 25 | $-5.8M | $-19.2M | ||
| Q1 25 | $-6.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-5.0M | — | ||
| Q2 24 | $-4.4M | — | ||
| Q1 24 | $-4.1M | — |
| Q4 25 | 61.5% | — | ||
| Q3 25 | 63.2% | 76.2% | ||
| Q2 25 | 60.3% | 76.2% | ||
| Q1 25 | 60.5% | — | ||
| Q4 24 | 61.3% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 63.5% | — | ||
| Q1 24 | 59.2% | — |
| Q4 25 | -67.7% | — | ||
| Q3 25 | -59.5% | -65.0% | ||
| Q2 25 | -61.6% | -53.2% | ||
| Q1 25 | -72.6% | — | ||
| Q4 24 | -72.5% | — | ||
| Q3 24 | -63.5% | — | ||
| Q2 24 | -60.1% | — | ||
| Q1 24 | -55.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | -66.5% | -74.3% | ||
| Q2 25 | -63.3% | -174.3% | ||
| Q1 25 | -71.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -61.2% | — | ||
| Q2 24 | -56.1% | — | ||
| Q1 24 | -54.3% | — |
| Q4 25 | $-0.26 | — | ||
| Q3 25 | $-0.21 | $-0.64 | ||
| Q2 25 | $-0.21 | $-165.53 | ||
| Q1 25 | $-0.22 | — | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.18 | — | ||
| Q2 24 | $-0.16 | — | ||
| Q1 24 | $-0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.9M | $54.9M |
| Total DebtLower is stronger | $49.1M | — |
| Stockholders' EquityBook value | $28.0M | $147.8M |
| Total Assets | $97.7M | $177.8M |
| Debt / EquityLower = less leverage | 1.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.9M | — | ||
| Q3 25 | $38.2M | $54.9M | ||
| Q2 25 | $41.5M | $27.1M | ||
| Q1 25 | $12.4M | — | ||
| Q4 24 | $20.1M | — | ||
| Q3 24 | $21.6M | — | ||
| Q2 24 | $32.8M | — | ||
| Q1 24 | $35.4M | — |
| Q4 25 | $49.1M | — | ||
| Q3 25 | $29.2M | — | ||
| Q2 25 | $28.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
| Q4 25 | $28.0M | — | ||
| Q3 25 | $15.9M | $147.8M | ||
| Q2 25 | $19.7M | $-78.2M | ||
| Q1 25 | $20.0M | — | ||
| Q4 24 | $25.4M | — | ||
| Q3 24 | $29.0M | — | ||
| Q2 24 | $32.1M | — | ||
| Q1 24 | $34.6M | — |
| Q4 25 | $97.7M | — | ||
| Q3 25 | $60.4M | $177.8M | ||
| Q2 25 | $62.9M | $77.8M | ||
| Q1 25 | $30.1M | — | ||
| Q4 24 | $39.2M | — | ||
| Q3 24 | $40.2M | — | ||
| Q2 24 | $52.6M | — | ||
| Q1 24 | $53.6M | — |
| Q4 25 | 1.75× | — | ||
| Q3 25 | 1.84× | — | ||
| Q2 25 | 1.46× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-8.6M |
| Free Cash FlowOCF − Capex | $-12.1M | $-11.4M |
| FCF MarginFCF / Revenue | -116.5% | -96.7% |
| Capex IntensityCapex / Revenue | 0.5% | 23.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-24.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | — | ||
| Q3 25 | $-3.1M | $-8.6M | ||
| Q2 25 | $-2.6M | $-11.3M | ||
| Q1 25 | $-6.2M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-2.7M | — | ||
| Q1 24 | $-3.8M | — |
| Q4 25 | $-12.1M | — | ||
| Q3 25 | $-3.3M | $-11.4M | ||
| Q2 25 | $-2.6M | $-13.6M | ||
| Q1 25 | $-6.4M | — | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -116.5% | — | ||
| Q3 25 | -37.5% | -96.7% | ||
| Q2 25 | -28.7% | -123.4% | ||
| Q1 25 | -74.9% | — | ||
| Q4 24 | -19.4% | — | ||
| Q3 24 | -14.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.2% | 23.9% | ||
| Q2 25 | 1.0% | 21.0% | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLPT
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | 45% |
| Biologics And Drug Delivery Services And License Fees | $2.8M | 27% |
| Biologics And Drug Delivery Disposable Products | $2.4M | 23% |
| Other | $502.0K | 5% |
SI
Segment breakdown not available.
